Clinical Trials

200 enrolled

Advanced Breast Cancer

NCT07371585 2026-03-27

TOP-REAL

300 enrolled

Breast Neoplasms

NCT07497386 2026-03-27

A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer

150 enrolled

Unresectable Locally Recurrent Breast Cancer

NCT04539938 2026-03-23

HER2CLIMB-04

70 enrolled 23 charts

Phase 2 Active not recruiting

Breast Neoplasms

NCT06048718 2026-03-10

TUXEDO-4

28 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT06750484 2026-02-27

Trial of Trastuzumab Deruxtecan in Previously Treated HER2

40 enrolled

Breast Cancer Metastatic

NCT07416253 2026-02-18

Trastuzumab Rezetecan vs Trastuzumab Deruxtecan in the Neoadjuvant Treatment of HER2 Positive Breast Cancer

68 enrolled

Breast Neoplasms

NCT07393425 2026-02-06

Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer

50 enrolled

Breast Neoplasms

NCT07368543 2026-01-28

STORM

216 enrolled

Breast Neoplasms

NCT06409390 2025-12-04

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

15 enrolled

Breast Neoplasms

NCT05982678 2025-11-26

ANISE

72 enrolled

HER2-positive Breast Cancer

NCT04986579 2025-11-19

Scalp Cooling in MBC

120 enrolled

Breast Neoplasms

NCT04553770 2025-11-10

Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

88 enrolled

Breast Neoplasms

NCT06533826 2025-10-24

TRADE DXd

357 enrolled

Breast Neoplasms

NCT06271837 2025-10-22

A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors

175 enrolled

Breast Neoplasms

NCT05795101 2025-09-19

TRUDI

63 enrolled

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT07151586 2025-09-03

ALTER

260 enrolled

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT07152782 2025-09-03

THUNDER

202 enrolled

Breast Cancer With Brain Metastasis

NCT05900206 2025-09-02

ARIADNE

370 enrolled

Breast Neoplasms

NCT07150208 2025-09-02

THUMB

140 enrolled

Breast Cancer With Brain Metastasis

NCT06172127 2025-07-29

DEMETHER

165 enrolled

253 enrolled 21 charts 2 FDA

Breast Neoplasms

NCT03248492 2025-06-26

DESTINY-Breast01

Phase 2 Terminated

Breast Neoplasms, Neoplasm Metastasis

NCT06439693 2025-06-26

The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

72 enrolled

Breast Neoplasms

NCT04420598 2025-06-24

DEBBRAH

41 enrolled 32 charts

BreastCNS

Brain Neoplasms, Breast Neoplasms, Neoplasm Metastasis, Meningeal Carcinomatosis

NCT06832202 2025-06-15

A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients

50 enrolled

HER2-low Hormone Receptor Positive Breast Cancer

NCT04132960 2025-06-12

DAISY

186 enrolled

Breast Neoplasms

NCT06797622 2025-01-28

Heterogeneity of 68Ga-FAPI Uptake As Imaging Biomarker in T-DXd Treatment for Brain Metastasis of HER2 Positive Breast Cancer

50 enrolled

Breast Neoplasms

NCT06102824 2024-11-25

ORIENTA

252 enrolled

Phase 2 Active not recruiting

HER2-negative Breast Cancer

NCT05710666 2024-08-05

Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast Cancer (SHAMROCK Study)

11 enrolled

HER2-positive Breast Cancer

NCT05953168 2023-07-19

T-DXd in the First-Line Treatment of Locally Advanced or Metastatic TNBC-LAR HER2-low Patients

69 enrolled

Triple Negative Breast Neoplasms

NCT04752059 2023-05-12

TUXEDO-1

15 enrolled